What question did this study set out to answer?

This research aims to evaluate the combined prognostic value of minimal residual disease (MRD) and cytogenetic risk classification in B‐ALL patients.

Integrated prognostic value of MRD and cytogenetics in adolescent and adult B‐cell acute lymphoblastic leukaemia

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis indicates MRD and cytogenetic risk significantly predict relapse in B-ALL patients, suggesting improved treatment strategies.

This research aims to evaluate the combined prognostic value of minimal residual disease (MRD) and cytogenetic risk classification in B‐ALL patients.
Retrospective analysis of 609 adolescent and adult patients with B‐ALL.
Evaluation of MRD at end of induction (MRD1) and after first consolidation (MRD2).
Comparison of MRD results with cytogenetic risk stratification (standard risk vs. poor risk).
MRD positivity at MRD1 and MRD2 predicted inferior 5-year relapse-free survival (RFS) and overall survival (OS) in poor-risk patients.
MRD1 and MRD2 were identified as independent predictors of relapse (RFS HR = 2.048) and mortality (OS HR = 1.979).
Allogeneic haematopoietic stem cell transplantation improved outcomes but did not eliminate high relapse risk in MRD2 positive patients.

Gu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis indicates MRD and cytogenetic risk significantly predict relapse in B-ALL patients, suggesting improved treatment strategies.